title: Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells.
abstract: Thiazolidinediones (TZD) are widely prescribed for the treatment of Type 2 diabetes. Increased loss of bone mass and a higher incidence of fractures have been associated with the use of this class of drugs in post-menopausal women. In vitro studies performed in rodent cell models indicated that rosiglitazone (RGZ), one of the TZD, inhibited osteoblastogenesis and induced adipogenesis in bone marrow progenitor cells. The objective of the present study was to determine for the first time the RGZ-dependent shift from osteoblastogenesis toward adipogenesis using a human cell model. To this purpose, bone marrow-derived mesenchymal stem cells were characterized and induced to differentiate along osteogenic and adipogenic lineages. We found that the exposure to RGZ potentiated adipogenic differentiation and shifted the differentiation toward an osteogenic phenotype into an adipogenic phenotype, as assessed by the appearance of lipid droplets. Accordingly, RGZ markedly increased the expression of the typical marker of adipogenesis fatty-acid binding protein 4, whereas it reduced the expression of Runx2, a marker of osteoblastogenesis. This is the first demonstration that RGZ counteracts osteoblastogenesis and induces a preferential differentiation into adipocytes in human mesenchymal stem cells.
authors.affiliation: Endocrine Unit, Department of Clinical Physiopathology, Center for Research, Transfer and High Education on Chronic, Inflammatory, Degenerative, and Neoplastic Disorders (DENOThe), University of Florence, 50139 Florence, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Benvenuti
authors.forename: I
authors.initials: I
authors.lastname: Cellai
authors.forename: P
authors.initials: P
authors.lastname: Luciani
authors.forename: C
authors.initials: C
authors.lastname: Deledda
authors.forename: S
authors.initials: S
authors.lastname: Baglioni
authors.forename: C
authors.initials: C
authors.lastname: Giuliani
authors.forename: R
authors.initials: R
authors.lastname: Saccardi
authors.forename: B
authors.initials: B
authors.lastname: Mazzanti
authors.forename: S
authors.initials: S
authors.lastname: Dal Pozzo
authors.forename: E
authors.initials: E
authors.lastname: Mannucci
authors.forename: A
authors.initials: A
authors.lastname: Peri
authors.forename: M
authors.initials: M
authors.lastname: Serio
mesh_terms: D017667:Adipocytes / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D050156:Adipogenesis / Q000187:drug effects*; D002454:Cell Differentiation / Q000187:drug effects*; D002478:Cells, Cultured; D050659:Core Binding Factor Alpha 1 Subunit / Q000378:metabolism; D050556:Fatty Acid-Binding Proteins / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D059630:Mesenchymal Stem Cells / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D008954:Models, Biological; D010006:Osteoblasts / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology*
chemical_list: D050659:Core Binding Factor Alpha 1 Subunit; C493410:FABP4 protein, human; D050556:Fatty Acid-Binding Proteins; D007004:Hypoglycemic Agents; C493709:RUNX2 protein, human; D045162:Thiazolidinediones; D000077154:Rosiglitazone